Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Energy Transfer LP announced a significant increase to its quarterly distribution alongside a multi-billion dollar capital expenditure plan for new pipeline and infrastructure projects, signaling confidence in its cash flow stability and long-term growth prospects.
Plains All American Pipeline's strategic pivot—selling its Canadian NGL unit for $3.8 billion to fund the acquisition of the EPIC Crude Oil Pipeline—has sharpened its focus on oil transportation. While a 10% distribution hike signals confidence, analyst downgrades and heightened options volatility ahead of earnings reveal deep divisions over the company's risk-reward profile.
National Fuel Gas (NFG) reported robust first-quarter earnings, driven by a 29% surge in upstream EBITDA. Executives highlighted progress on pipeline expansions, strategic hedging against volatile gas prices, and the planned acquisition of CenterPoint's Ohio utility, while reaffirming full-year guidance.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
